On This Day in Health: February 9, 2017
On February 9, 2017, the United States Food and Drug Administration approved deflazacort, sold as Emflaza, to treat Duchenne muscular dystrophy in patients five years of age and older. The authorization covered tablets and an oral suspension. It was the first FDA approval of a corticosteroid specifically for this disease, although clinicians had already used corticosteroids in Duchenne care. The date therefore marks a particular regulatory decision rather than the discovery of steroid treatment or the arrival of a cure. It added an approved option for a progressive genetic condition that affects patients, families, and multidisciplinary care teams over many years.
Duchenne muscular dystrophy is associated with changes in the gene responsible for dystrophin, a protein important to muscle structure. Without enough functional dystrophin, muscle fibers become vulnerable to damage, and weakness generally worsens over time. The condition primarily affects boys and can involve muscles used for movement, breathing, and heart function. Care extends well beyond any single medicine, drawing on rehabilitation, respiratory support, cardiac assessment, and other services. This background explains why an additional treatment option mattered, but also why it could not be understood as a complete answer to the disease. Patients' needs change as the condition progresses, and treatment goals include preserving function and supporting everyday life.
Deflazacort is a corticosteroid, a class of medicine with anti-inflammatory effects. The evidence considered for approval included a clinical study that compared muscle strength in treated patients with patients receiving placebo. FDA described an improvement in strength at an early assessment and maintenance of an overall stability advantage through a longer study period. Such results supported the medicine's authorized use, but they did not show that the underlying genetic change had been corrected. The regulator also identified adverse effects associated with corticosteroid treatment. Growth, weight, infection risk, and other health considerations remain relevant when evaluating this class of medicine, especially during childhood and prolonged use.
The February 9 milestone illustrates the difference between scientific practice, formal authorization, and broader access. A medicine can have a history of use elsewhere before receiving an indication from a particular national regulator. Approval then establishes the conditions under which it may be marketed in that jurisdiction, without guaranteeing that cost or availability will be simple for every family. In Duchenne care, the decision formed part of a continuing search for treatments that could change the disease's course. Its historical importance should be stated alongside its limits: an approved steroid offered another tool, while ongoing clinical support and research remained essential. The patient-centered meaning of progress lies in function, participation, and quality of life as well as in regulatory milestones.
Duchenne care already included corticosteroids before this authorization. The milestone concerns the first FDA approval of a corticosteroid specifically for the condition.
The disease involves inadequate functional dystrophin and progressive muscle damage. Its effects can extend to breathing and cardiac function, making coordinated care important.
The initial authorization covered patients five and older and included two oral forms. Later labeling changes belong to a separate regulatory history.
Trial evidence supported a muscle-strength benefit. That finding did not establish correction of the genetic cause or elimination of future disease progression.
The approval added an option within multidisciplinary care. Rehabilitation and other support remained central to patients' changing needs.
Regulatory authorization and affordable access are separate milestones. A treatment's practical value depends on whether families can obtain appropriate continuing care.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.